Difference between revisions of "Alisertib (MLN-8237)"
Jump to navigation
Jump to search
m |
m |
||
| Line 4: | Line 4: | ||
=Preliminary results= | =Preliminary results= | ||
| − | =[[Aggressive Non-Hodgkin lymphoma]]= | + | ==[[Aggressive Non-Hodgkin lymphoma]]== |
| − | =[[Mantle cell lymphoma]]= | + | ==[[Mantle cell lymphoma]]== |
# Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. [http://jco.ascopubs.org/content/32/1/44.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24043741 PubMed] | # Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. [http://jco.ascopubs.org/content/32/1/44.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24043741 PubMed] | ||
| − | [[Category: | + | [[Category:Drug index]] |
| + | [[Category:Chemotherapy]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:Aurora kinase inhibitors]] | [[Category:Aurora kinase inhibitors]] | ||
| Line 15: | Line 16: | ||
[[Category:Aggressive Non-Hodgkin lymphoma medications]] | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 00:29, 26 November 2014
Mechanism of action
Aurora A kinase (AAK) inhibitor
Preliminary results
Aggressive Non-Hodgkin lymphoma
Mantle cell lymphoma
- Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. link to original article PubMed